Treatment of pruritus in mild-to-moderate atopic dermatitis with a topical non-steroidal agent

Journal of Drugs in Dermatology

Volumn 8, Issue 6, 2009, Pages 537-539

  Veraldi, Stefano ^a   De Micheli, Paolo ^b   Schianchi, Rossana ^b   Lunardon, Luisa ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b European Institute of Dermatology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATOPICLAIR; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; ZARZENDA; DERMATOLOGICAL AGENT; GLYCYRRHETINIC ACID; MAS063DP; PLANT EXTRACT;

ADULT; APPLICATION SITE BURNING; ARTICLE; ATOPIC DERMATITIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRURITUS; VISUAL ANALOG SCALE; ADOLESCENT; CLINICAL TRIAL; DRUG COMBINATION; FAT INTAKE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DIETARY FATS; DRUG COMBINATIONS; FEMALE; GLYCYRRHETINIC ACID; HUMANS; MALE; PLANT EXTRACTS; PRURITUS;

EID: 67650227696     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Zhai H, Villarama CD, Hafeez ZH, Maibach HI. Efficacy of a topical agent, MAS063D (Atopiclair®), in the treatment of sodium lauryl sulphate-induced irritant contact dermatitis. A double-blind, vehicle-controlled study. Exogenous Dermatol. 2003;2:301-305. (Pubitemid 39656692)
2. Belloni G, Pinelli S, Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of of MAS063D (Atopiclair®), in the treatment of mild to moderate atopic dermatitis. Eur J Dermatol. 2005;15(1):31-36. (Pubitemid 40254620)
3. Abramovits W, Gover M, Gupta A. Atopiclair nonsteroidal cream. Skinmed. 2005;4(6):369.
4. Abramovits W, Hebert A, Boguniewicz M. A multicenter randomized, vehicle-controlled, double-blind clinical study to examine the safety and efficacy of MAS063DP in the management of AD. J Am Acad Dermatol. 2006; 54(Suppl):AB84.
5. Abramovits W, Boguniewicz M. A multicenter, randomized, vehicle-controlled clinical study to examine the safety and efficacy of MAS-063DP in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol. 2006;5(3):236-244.
6. Abramovits W, Perlmutter A. Atopiclair™. Its position within a topical paradigm for the treatment of atopic dermatitis. Expert Rev Dermatol. 2007; 2:115-119.
7. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;92(Suppl):44-47.
8. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol. 1989;144(Suppl):13-14. (Pubitemid 19228703)
9. Aitken RC. Measurement of feeling using visual analogue scales. Proc R Soc Med. 1969;62(10):989-993.
10. Grassi L, Moretti M, Bisetti A. Un nuovo farmaco mucoattivo con attivitàanti-proteasica: La telmesteina. Riv Ital Biol Med. 1992;12:67-74.
11. Lerner EA. Chemical mediators of itching. In: Bernhard JD, ed. Itch. Mechanisms and management of pruritus. New York: McGraw-Hill, 1994:23-35.